BNGO:NSD-Bionano Genomics Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 5.27

Change

+0.07 (+1.35)%

Market Cap

USD 1.44B

Volume

4.63M

Avg Analyst Target

USD 10.00 (+89.75%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-19 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

+3.55 (+0.86%)

USD64.25B 78.62 54.32
IDXX IDEXX Laboratories Inc

+2.70 (+0.42%)

USD54.30B 76.10 57.14
DXCM DexCom Inc

+8.77 (+1.62%)

USD52.37B 101.40 115.62
ICLR ICON Public Limited Company

+1.01 (+0.37%)

USD22.04B 40.33 40.36
EXAS Exact Sciences Corporation

+0.69 (+0.72%)

USD16.48B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
NTRA Natera Inc

+2.28 (+2.05%)

USD10.45B N/A N/A
GH Guardant Health Inc

+5.62 (+5.65%)

USD10.29B N/A N/A
SYNH Syneos Health Inc

+0.39 (+0.45%)

USD9.01B 38.87 20.82
MEDP Medpace Holdings Inc

-0.15 (-0.08%)

USD6.66B 40.06 30.06

ETFs Containing BNGO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 71.10% 91% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.10% 91% A- 90% A-
Trailing 12 Months  
Capital Gain 858.18% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 858.18% 100% A+ 99% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 257.71% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 257.71% 95% A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 565.48% 7% F 3% F
Risk Adjusted Return 45.57% 59% F 62% D-
Market Capitalization 1.44B 60% D- 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.12 51% F 34% F
Price / Cash Flow Ratio -37.59 93% A 85% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -29.15% 47% F 36% F
Return on Invested Capital -102.74% 16% F 7% F
Return on Assets -15.46% 39% F 23% F
Debt to Equity Ratio 46.54% 41% F 40% F
Technical Ratios  
Short Ratio 5.19 59% F 28% F
Short Percent 14.61% 9% F 11% F
Beta 1.98 13% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.